Michele W L Teng

List of Publications by Year in Descending Order

112 papers	12,319 citations	56 h-index	110 g-index
129 ext. papers	15,189 ext. citations	11.9 avg, IF	6.78 L-index

#	Paper	IF	Citations
112	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.. *JHEP Reports*, **2022**, 4, 100386	10.3	3
111	Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.. *Science Translational Medicine*, **2022**, 14, eabj9779	17.5	2
110	A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. *Radiation Oncology*, **2021**, 16, 69	4.2	3
109	Systemic administration of IL-33 induces a population of circulating KLRG1 type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. *Immunology and Cell Biology*, **2021**, 99, 65-83	5	3
108	Control of Metastases via Myeloid CD39 and NK Cell Effector Function. *Cancer Immunology Research*, **2020**, 8, 356-367	12.5	31
107	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. *Clinical Cancer Research*, **2020**, 26, 3671-3681	12.9	27
106	MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1. *Cancer Discovery*, **2020**, 10, 124-141	24.4	50
105	Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy **2020**, 8,		6
104	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. *Nature Immunology*, **2020**, 21, 1205-1218	19.1	24
103	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. *Clinical Cancer Research*, **2019**, 25, 5743-5751	12.9	73
102	CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function. *Cancer Immunology Research*, **2019**, 7, 559-571	12.5	41
101	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. *OncoImmunology*, **2019**, 8, e1581530	7.2	31
100	The role of NK cells and CD39 in the immunological control of tumor metastases. *OncoImmunology*, **2019**, 8, e1593809	7.2	38
99	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. *Cancer Discovery*, **2019**, 9, 1754-1773	24.4	86
98	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. *JCI Insight*, **2019**, 5,	9.9	11
97	Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. *Journal of Clinical Oncology*, **2019**, 37, TPS129-TPS129	2.2	
96	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. *Cancer Discovery*, **2019**, 9, 1511-1519	24.4	13

95	IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection. *Science Immunology*, **2019**, 4,	28	39
94	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). *Trials*, **2019**, 20, 753	2.8	10
93	Batf3 DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. *OncoImmunology*, **2019**, 8, e1546068	7.2	20
92	Cancer immunoediting and resistance to T cell-based immunotherapy. *Nature Reviews Clinical Oncology*, **2019**, 16, 151-167	19.4	518
91	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. *OncoImmunology*, **2018**, 7, e1431088	7.2	45
90	Purinergic Receptors: Novel Targets for Cancer Immunotherapy **2018**, 115-141		2
89	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. *OncoImmunology*, **2018**, 7, e1424677	7.2	27
88	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. *OncoImmunology*, **2018**, 7, e1445949	7.2	19
87	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. *Seminars in Cancer Biology*, **2018**, 48, 91-103	12.7	164
86	Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	58
85	TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma. *Blood*, **2018**, 132, 1689-1694	2.2	131
84	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23. *Cancer Immunology Research*, **2018**, 6, 978-987	12.5	9
83	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. *Journal of Clinical Investigation*, **2018**, 128, 2613-2625	15.9	66
82	Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. *Nature Reviews Clinical Oncology*, **2018**, 15, 676-693	19.4	46
81	IL-23 promotes the development of castration-resistant prostate cancer. *Immunology and Cell Biology*, **2018**, 96, 883-885	5	4
80	Resistance to PD1/PDL1 checkpoint inhibition. *Cancer Treatment Reviews*, **2017**, 52, 71-81	14.4	305
79	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. *Clinical Cancer Research*, **2017**, 23, 5789-5801	12.9	47
78	Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. *OncoImmunology*, **2017**, 6, e1312044	7.2	15

77	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. *Clinical Cancer Research*, **2017**, 23, 2478-2490	12.9	71
76	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*, **2017**, 47, 789-802.e9	32.3	142
75	Targeting immunosuppressive adenosine in cancer. *Nature Reviews Cancer*, **2017**, 17, 709-724	31.3	304
74	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. *Nature Immunology*, **2017**, 18, 1004-1015	19.1	330
73	De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncology, The*, **2017**, 18, e731-e741	27.1	383
72	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. *Blood Advances*, **2017**, 1, 341-351	7.8	23
71	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. *Cancer Research*, **2016**, 76, 6266-6277	10.1	57
70	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. *Clinical Cancer Research*, **2016**, 22, 5183-5188	12.9	127
69	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. *Genome Medicine*, **2016**, 8, 111	14.4	40
68	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. *Cancer Discovery*, **2016**, 6, 446-59	24.4	147
67	Combination cancer immunotherapies tailored to the tumour microenvironment. *Nature Reviews Clinical Oncology*, **2016**, 13, 143-58	19.4	561
66	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. *JCI Insight*, **2016**, 1, e86850	9.9	33
65	Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. *Cancer Cell*, **2016**, 30, 391-403	24.3	216
64	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. *Cancer Discovery*, **2016**, 6, 1382-1399	24.4	356
63	Checkpoint Immunotherapy: Picking a Winner. *Cancer Discovery*, **2016**, 6, 818-20	24.4	7
62	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. *Cancer Research*, **2016**, 76, 5288-301	10.1	59
61	Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. *Journal of Experimental Medicine*, **2015**, 212, 1303-21	16.6	69
60	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. *Nature Medicine*, **2015**, 21, 719-29	50.5	488

59	Classifying Cancers Based on T-cell Infiltration and PD-L1. *Cancer Research*, **2015**, 75, 2139-45	10.1	864
58	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. *Journal of Clinical Investigation*, **2015**, 125, 2077-89	15.9	69
57	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. *Blood*, **2015**, 126, 1609-20	2.2	78
56	TIGIT predominantly regulates the immune response via regulatory T cells. *Journal of Clinical Investigation*, **2015**, 125, 4053-62	15.9	317
55	From mice to humans: developments in cancer immunoediting. *Journal of Clinical Investigation*, **2015**, 125, 3338-46	15.9	188
54	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. *Cell Research*, **2015**, 25, 208-24	24.7	126
53	Cancer. Can cancer trigger autoimmunity?. *Science*, **2014**, 343, 147-8	33.3	8
52	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. *Clinical and Translational Immunology*, **2014**, 3, e22	6.8	48
51	Role of IL-17 and IL-22 in autoimmunity and cancer. *Actas Dermo-sifiliográficas*, **2014**, 105 Suppl 1, 41-50	0.5	24
50	Translational biology of osteosarcoma. *Nature Reviews Cancer*, **2014**, 14, 722-35	31.3	644
49	Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. *Molecular Therapy*, **2014**, 22, 18-27	11.7	83
48	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. *Cancer Research*, **2014**, 74, 3652-8	10.1	178
47	Targeting regulatory T cells in tumor immunotherapy. *Immunology and Cell Biology*, **2014**, 92, 473-4	5	23
46	Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. *Cancer Research*, **2014**, 74, 2412-21	10.1	29
45	Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression. *OncoImmunology*, **2014**, 3, e28964	7.2	6
44	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. *OncoImmunology*, **2014**, 3, e958952	7.2	18
43	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. *Cancer Research*, **2014**, 74, 436-45	10.1	90
42	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. *OncoImmunology*, **2014**, 3, e963395	7.2	7

41	The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. *OncoImmunology*, **2013**, 2, e23036	7.2	8
40	A balance of interleukin-12 and -23 in cancer. *Trends in Immunology*, **2013**, 34, 548-55	14.4	85
39	Cancer Immunoediting **2013**, 85-99		3
38	TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. *OncoImmunology*, **2013**, 2, e23849	7.2	193
37	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. *Journal of Experimental Medicine*, **2012**, 209, 1869-82	16.6	221
36	Both IFN-and IL-17 are required for the development of severe autoimmune gastritis. *European Journal of Immunology*, **2012**, 42, 2574-83	6.1	15
35	Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. *Cancer Research*, **2012**, 72, 3987-96	10.1	76
34	Stable IL-10: a new therapeutic that promotes tumor immunity. *Cancer Cell*, **2011**, 20, 691-3	24.3	23
33	Biology and clinical observations of regulatory T cells in cancer immunology. *Current Topics in Microbiology and Immunology*, **2011**, 344, 61-95	3.3	27
32	Prospects for TIM3-Targeted Antitumor Immunotherapy. *Cancer Research*, **2011**, 71, 6567-71	10.1	99
31	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 4141-6	11.5	88
30	Anti-TIM3 antibody promotes T cell IFN-mediated antitumor immunity and suppresses established tumors. *Cancer Research*, **2011**, 71, 3540-51	10.1	396
29	CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. *Cancer Research*, **2011**, 71, 2892-900	10.1	297
28	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7142-7	11.5	334
27	Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. *Cancer Research*, **2011**, 71, 2077-86	10.1	38
26	Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. *Cancer Research*, **2010**, 70, 2665-74	10.1	62
25	Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. *Cancer Research*, **2010**, 70, 7800-9	10.1	153
24	IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 8328-33	11.5	101

23	Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. *Journal of Immunology*, **2010**, 184, 5493-501	5.3	70
22	Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. *Cancer Research*, **2010**, 70, 7788-99	10.1	201
21	Does IL-17 suppress tumor growth?. *Blood*, **2010**, 115, 2554-5; author reply 2556-7	2.2	25
20	CD1d activation and blockade: a new antitumor strategy. *Journal of Immunology*, **2009**, 182, 3366-71	5.3	24
19	CD1d-based combination therapy eradicates established tumors in mice. *Journal of Immunology*, **2009**, 183, 1911-20	5.3	22
18	Immune-mediated dormancy: an equilibrium with cancer. *Journal of Leukocyte Biology*, **2008**, 84, 988-93	6.5	205
17	Interleukin 21 enhances antibody-mediated tumor rejection. *Cancer Research*, **2008**, 68, 3019-25	10.1	22
16	Antitumor activity of dual-specific T cells and influenza virus. *Cancer Gene Therapy*, **2007**, 14, 499-508	5.4	21
15	Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. *Cancer Research*, **2007**, 67, 7495-504	10.1	57
14	CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. *Journal of Immunology*, **2006**, 176, 1582-7	5.3	323
13	Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy. *Human Gene Therapy*, **2006**, 17, 1134-43	4.8	19
12	Adoptive Transfer of Chimeric Fc?RI Gene-Modified Human T Cells for Cancer Immunotherapy. *Human Gene Therapy*, **2006**, 061019064400001	4.8	
11	Gene modification strategies to induce tumor immunity. *Immunity*, **2005**, 22, 403-14	32.3	52
10	Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. *Blood*, **2005**, 106, 2995-3003	2.2	82
9	Supernatural T cells: genetic modification of T cells for cancer therapy. *Nature Reviews Immunology*, **2005**, 5, 928-40	36.5	129
8	T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner. *Journal of Biological Chemistry*, **2005**, 280, 38235-41	5.4	10
7	Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 19051-6	11.5	124
6	Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. *Human Gene Therapy*, **2004**, 15, 699-708	4.8	43

5	Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. *Journal of Immunology*, **2004**, 173, 2143-50	5.3	65
4	A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. *Cancer Gene Therapy*, **2004**, 11, 371-9	5.4	51
3	Cytotoxic lymphocytes; instigators of dramatic target cell death. *Biochemical Pharmacology*, **2004**, 68, 1033-40	6	28
2	Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. *Journal of Immunology*, **2002**, 169, 5780-6	5.3	87
1	Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. *Blood*, **2002**, 100, 3155-63	2.2	142